Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $222 |
| Triangulated Fair Value | $208 |
| 12-mo Scenario PWEV | $217 |
| Implied Return | -6% |
| Forward P/E | 15.3x |
| Market Cap | $14B |
| 52-Week Range | $101 – $215 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate / Deleveraging' (8% weight) — targets $389, +75% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($222) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement Cuts / Labor Inflation' (20%) — targets $86, -61% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 65% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.14 vs analyst floor +0.01 → delta +0.13 (n=22 mgmt / 18 Q&A; 3th pctile across the S&P book, z -1.6).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.14 | +0.01 | +0.13 |
| 2025Q4 | +0.25 | +0.15 | +0.10 |
| 2025Q3 | +0.10 | +0.00 | +0.10 |
| 2025Q2 | +0.21 | +0.11 | +0.10 |
News (last 365d, 781 articles): avg ticker sentiment +0.17 (bullish 31% / bearish 6%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement Cuts / Labor Inflation' downside ($86) to a 'Bull — Re-Rate / Deleveraging' bull case ($389); the probability-weighted blend (PWEV $217) is -2% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement Cuts / Labor Inflation | 20% | $86 | -61% |
| Volume / Payer-Mix Recession | 17% | $164 | -26% |
| Base — Admissions + Pricing | 35% | $228 | +2% |
| Growth — Volume Recovery / Service-Line | 20% | $308 | +38% |
| Bull — Re-Rate / Deleveraging | 8% | $389 | +75% |
| Probability-Weighted (PWEV) | — | $217 | -2% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement Cuts / Labor Inflation (20%, $86). Structural impairment — reimbursement cuts / labor inflation: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 85.85; probability: 0.2.
- Volume / Payer-Mix Recession (17%, $164). Cyclical downturn — patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage weakens for 1–2 years before normalising. Drivers — implied_target: 164.13; probability: 0.17.
- Base — Admissions + Pricing (35%, $228). Mid-cycle — normalised patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage; disciplined capital allocation; steady returns. Drivers — implied_target: 227.96; probability: 0.35.
- Growth — Volume Recovery / Service-Line (20%, $308). Upside — volume recovery + deleveraging lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 307.74; probability: 0.2.
- Bull — Re-Rate / Deleveraging (8%, $389). Upside tail — sustained tight conditions or a structural re-rate on volume recovery + deleveraging. Drivers — implied_target: 388.67; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $192 | -14% |
| Peer P/E re-rate | multiple | $210 | -6% |
| Peer EV/Revenue re-rate | multiple | $71 | -68% |
| Scenario PWEV | multiple | $217 | -2% |
| DCF (5-year + terminal) | cash flow + terminal × | $4 | -98% |
| Triangulated (weighted) | — | $208 | -6% |
DCF excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $192 and 40% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (65% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 9.0%, 13x terminal FCF multiple → $4. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.495x) implies $210. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Hospital / Dialysis Operations | $13.8B | 100% | 4% | 9% | 15x | 7% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage |
| net_debt_or_cash_b | -12.49 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.07 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement cuts / labor inflation |
| upside | volume recovery + deleveraging |
Industry Context — Health Payers Providers
This name sits in the Health Payers Providers as a providers. patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Cost-Trend Spike / Reimbursement-Reform Squeeze | 37% | 37% | |
| Mid-Cycle — Membership & Volume Growth | 35% | 35% | |
| Upside — Margin Recovery / Care-Services | 28% | 28% |
On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $14B | $1B | $1B | $1B | $1B | $1B |
| FY+2 | $15B | $1B | $1B | $1B | $1B | $1B |
| FY+3 | $15B | $1B | $1B | $1B | $1B | $1B |
| FY+4 | $16B | $1B | $1B | $1B | $1B | $1B |
| FY+5 | $16B | $1B | $1B | $1B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 13x | $9B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 7% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 9.0% · Σ PV(FCF) $4B + PV(terminal) $9B = EV $13B; + net cash → equity $0B ÷ diluted shares 0.06B = $4/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $34/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 4% vs WACC 9% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| CVS | 0.49x | 14.2x | 8% | 4% |
| CI | 0.353x | 9.29x | 8% | 6% |
| DGX | 2.558x | 19.19x | 3% | 14% |
| LH | 1.98x | 14.79x | 3% | 11% |
| Median | 1.2349999999999999x | 14.495x | — | — |
Peer-median fwd P/E → $210; EV/Rev → $71.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| Scenario PWEV | $217 | 50% | $109 |
| Monte Carlo median | $192 | 30% | $57 |
| Peer P/E | $210 | 20% | $42 |
| Triangulated | — | 100% | $208 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 9.1x | 11.0x | 13.0x | 14.9x | 16.9x |
|---|---|---|---|---|---|
| 7% | $-25 | $-2 | $21 | $43 | $67 |
| 8% | $-31 | $-10 | $13 | $34 | $56 |
| 9% | $-37 | $-17 | $4 | $25 | $46 |
| 10% | $-43 | $-24 | $-3 | $16 | $36 |
| 11% | $-49 | $-30 | $-11 | $8 | $27 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $-71 | $-40 | $-9 | $22 | $53 |
| -1.5pp | $-69 | $-35 | $-2 | $31 | $64 |
| +0.0pp | $-66 | $-31 | $4 | $40 | $75 |
| +1.5pp | $-64 | $-26 | $11 | $49 | $86 |
| +3.0pp | $-61 | $-21 | $19 | $58 | $98 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $-66 | $75 | $141 |
| Terminal × ±15% | $-16 | $25 | $42 |
| Revenue CAGR ±3pp | $-9 | $19 | $27 |
| WACC ±1pp | $-3 | $13 | $16 |
| FCF conversion ±10% | $4 | $4 | $0 |
Company lever — SoP/share vs Hospital / Dialysis Operations multiple (AI re-rating) (base 15x)
| Multiple | 10.5x | 12.8x | 15.0x | 17.2x | 19.5x |
|---|---|---|---|---|---|
| SoP/share | $2,069 | $2,565 | $3,039 | $3,514 | $4,010 |
Load-Bearing Assumptions
DCF: WACC 9%, terminal multiple 13×, FY+5 revenue $16B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
DCF $4 vs MC median $192 diverge by 98%. Investigate which assumptions differ. A miss on Gross Margin drops the case toward the structural target $86.
Fact / Inference / Speculation
- FACT: Spot $222; 52-week range $101–$215; engine rating HOLD; base-case target $218 (-2%).
- INFERENCE: Triangulated FV $208 (-6%). Gross Margin explains 65% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 65% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $124 (-44% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (65% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).